Coronary heart disease secondary prevention beta-blockers: Difference between revisions
Esther Lee (talk | contribs) (/* Beta Blockers (DO NOT EDIT) {{cite journal| author=Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA et al.| title=AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Va...) |
|||
(3 intermediate revisions by 2 users not shown) | |||
Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==2011 AHA/ACCF Guidelines for Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease (DO NOT EDIT) <ref name="pmid22052934">{{cite journal| author=Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA et al.| title=AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. | journal=Circulation | year= 2011 | volume= 124 | issue= 22 | pages= 2458-73 | pmid=22052934 | doi=10.1161/CIR.0b013e318235eb4d | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22052934 }} </ref>== | ==2011 AHA/ACCF Guidelines for Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease (DO NOT EDIT) <ref name="pmid22052934">{{cite journal| author=Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA et al.| title=AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. | journal=Circulation | year= 2011 | volume= 124 | issue= 22 | pages= 2458-73 | pmid=22052934 | doi=10.1161/CIR.0b013e318235eb4d | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22052934 }} </ref>== | ||
Line 23: | Line 21: | ||
|- | |- | ||
|bgcolor="LemonChiffon"| | |bgcolor="LemonChiffon"| | ||
<nowiki>"</nowiki>1. It is reasonable to continue [[Beta blockers|β-blockers]] beyond 3 years as chronic therapy in all patients with normal [[left ventricular function]] who have had [[myocardial infarction]] or [[ACS]]. <ref name="pmid10381708">{{cite journal |author=Freemantle N, Cleland J, Young P, Mason J, Harrison J |title=beta Blockade after myocardial infarction: systematic review and meta regression analysis |journal=BMJ |volume=318 |issue=7200 |pages=1730–7 |year=1999 |month=June |pmid=10381708 |pmc=31101 |doi= |url=}}</ref><ref name="urlBeta blockers for preventing stroke recurrence - The Cochrane Library - De Lima - Wiley Online Library">{{cite web |url=http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007890/abstract |title=Beta blockers for preventing stroke recurrence - The Cochrane Library - De Lima - Wiley Online Library |format= |work= |accessdate=}}</ref> ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: B'']])<nowiki>"</nowiki> | <nowiki>"</nowiki>'''1.''' It is reasonable to continue [[Beta blockers|β-blockers]] beyond 3 years as chronic therapy in all patients with normal [[left ventricular function]] who have had [[myocardial infarction]] or [[ACS]]. <ref name="pmid10381708">{{cite journal |author=Freemantle N, Cleland J, Young P, Mason J, Harrison J |title=beta Blockade after myocardial infarction: systematic review and meta regression analysis |journal=BMJ |volume=318 |issue=7200 |pages=1730–7 |year=1999 |month=June |pmid=10381708 |pmc=31101 |doi= |url=}}</ref><ref name="urlBeta blockers for preventing stroke recurrence - The Cochrane Library - De Lima - Wiley Online Library">{{cite web |url=http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007890/abstract |title=Beta blockers for preventing stroke recurrence - The Cochrane Library - De Lima - Wiley Online Library |format= |work= |accessdate=}}</ref> ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: B'']])<nowiki>"</nowiki> | ||
|- | |- | ||
|bgcolor="LemonChiffon"| | |bgcolor="LemonChiffon"| | ||
<nowiki>"</nowiki>2. It is reasonable to give [[Beta blockers|β-blocker]] therapy in patients with [[left ventricular systolic dysfunction]] ([[ejection fraction]] ≤40%) without [[heart failure]] or prior [[myocardial infarction]]. ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: C'']])<nowiki>"</nowiki> | <nowiki>"</nowiki>'''2.''' It is reasonable to give [[Beta blockers|β-blocker]] therapy in patients with [[left ventricular systolic dysfunction]] ([[ejection fraction]] ≤40%) without [[heart failure]] or prior [[myocardial infarction]]. ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: C'']])<nowiki>"</nowiki> | ||
|} | |} | ||
Line 34: | Line 32: | ||
|- | |- | ||
|bgcolor="LemonChiffon"| | |bgcolor="LemonChiffon"| | ||
<nowiki>"</nowiki>1. [[Beta blockers|β-Blockers]] may be considered as chronic therapy for all other patients with coronary or other [[vascular disease]]. ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: C'']])<nowiki>"</nowiki> | <nowiki>"</nowiki>'''1.''' [[Beta blockers|β-Blockers]] may be considered as chronic therapy for all other patients with coronary or other [[vascular disease]]. ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: C'']])<nowiki>"</nowiki> | ||
|} | |} | ||
== References == | == References == | ||
Line 46: | Line 41: | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Needs overview]] | |||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Cardiology]] | [[Category:Cardiology]] |
Latest revision as of 14:29, 11 January 2013
Coronary heart disease Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Coronary heart disease secondary prevention beta-blockers On the Web |
American Roentgen Ray Society Images of Coronary heart disease secondary prevention beta-blockers |
FDA on Coronary heart disease secondary prevention beta-blockers |
CDC on Coronary heart disease secondary prevention beta-blockers |
Coronary heart disease secondary prevention beta-blockers in the news |
Blogs on Coronary heart disease secondary prevention beta-blockers |
Risk calculators and risk factors for Coronary heart disease secondary prevention beta-blockers |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
2011 AHA/ACCF Guidelines for Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease (DO NOT EDIT) [1]
Beta Blockers (DO NOT EDIT) [1]
Class I |
"1. β-Blocker therapy should be used in all patients with left ventricular systolic dysfunction (ejection fraction ≤40%) with heart failure or prior myocardial infarction, unless contraindicated. (Use should be limited to carvedilol, metoprolol succinate, or bisoprolol, which have been shown to reduce mortality.) [2][3] (Level of Evidence: A)" |
"2. β-Blocker therapy should be started and continued for 3 years in all patients with normal left ventricular function who have had myocardial infarction or ACS. [4][5] (Level of Evidence: B)" |
Class IIa |
"1. It is reasonable to continue β-blockers beyond 3 years as chronic therapy in all patients with normal left ventricular function who have had myocardial infarction or ACS. [4][5] (Level of Evidence: B)" |
"2. It is reasonable to give β-blocker therapy in patients with left ventricular systolic dysfunction (ejection fraction ≤40%) without heart failure or prior myocardial infarction. (Level of Evidence: C)" |
Class IIb |
"1. β-Blockers may be considered as chronic therapy for all other patients with coronary or other vascular disease. (Level of Evidence: C)" |
References
- ↑ 1.0 1.1 Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA; et al. (2011). "AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation". Circulation. 124 (22): 2458–73. doi:10.1161/CIR.0b013e318235eb4d. PMID 22052934.
- ↑ Packer M, Bristow MR, Cohn JN; et al. (1996). "The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group". N. Engl. J. Med. 334 (21): 1349–55. doi:10.1056/NEJM199605233342101. PMID 8614419. Unknown parameter
|month=
ignored (help) - ↑ Domanski MJ, Krause-Steinrauf H, Massie BM; et al. (2003). "A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS". J. Card. Fail. 9 (5): 354–63. PMID 14583895. Unknown parameter
|month=
ignored (help) - ↑ 4.0 4.1 Freemantle N, Cleland J, Young P, Mason J, Harrison J (1999). "beta Blockade after myocardial infarction: systematic review and meta regression analysis". BMJ. 318 (7200): 1730–7. PMC 31101. PMID 10381708. Unknown parameter
|month=
ignored (help) - ↑ 5.0 5.1 "Beta blockers for preventing stroke recurrence - The Cochrane Library - De Lima - Wiley Online Library".